Deborah Dunsire has more than 30 years of clinical, commercial, and international management experience from the biotech and pharmaceutical industry, primarily in the fields of oncology and CNS, thus bringing a breadth of scientific and business experience. Her professional and executive experience includes positions as President and CEO of XTuit Pharmaceuticals, Inc., FORUM Pharmaceuticals Inc. and Millennium Pharmaceuticals, Inc. Deborah joined Lundbeck as President & CEO in September 2018.

Deborah graduated from University of the Witwatersrand, South Africa in 1985 and is trained as a medical doctor.

Deborah serves as a Member of the Board of Directors Ultragenyx Pharmaceutical Inc. and Syros Pharmaceuticals.

Having completed his degree, Lars Bang began his career at Lundbeck in 1988 as a trainee in R&D. Subsequently, he has head R&D Planning, Corporate Planning and Strategy, Lundbeck España S.A, Group Sales & Marketing. In 2003 he was appointed Group Senior Vice President Supply Operations & Engineering.

Lars holds a Master of Science degree in Engineering from the Technical University of Denmark and a Bachelor of Commerce degree in Marketing from the Copenhagen Business School.

Tom joined Lundbeck in February 2023 as an accomplished executive with more than 25 years of diverse corporate, general management and commercial leadership experience, including roles in Executive Management, Marketing, Sales, Commercial Operations, Customer Insights and Analytics and Finance at small, mid-size and large pharmaceutical companies. Prior to Lundbeck, Tom served as Chief Executive Officer and Global Business Leader of Vectura Inc.  Prior to his role at Vectura Inc., Tom held several Chief Commercial Officer roles, developing Commercial strategy and overseeing execution for U.S., Canadian and European markets at pharmaceutical companies with strong central nervous system (CNS) franchises, including a role as Chief Commercial Officer at Sunovion. He has also served as Head of General Medicines in the U.S. for Takeda.

Tom holds a BS in Economics with a dual concentration in finance and marketing from the Wharton School of the University of Pennsylvania and an M.B.A. from the Wharton School of Business.

Elise brings close to 20 years of global and strategic people development across a broad spectrum of companies and industries. She joins Lundbeck from SimCorp, a financial technology company, as Senior Vice President and Chief Human Resources Officer since 2014. Elise started her career working with insurance and pension in the financial industry at Nordea and moved to Microsoft, where she lived in Seattle for a period of time. Before SimCorp Elise held senior HR positions in Nycomed, Switzerland, and was part of the Takeda acquisition and integration.

Elise holds a Masters in Law from the University of Copenhagen and serves on the Board of Directors of CBS Executive Fonden.

Joerg Hornstein started his career with Merck KGaA, where he spent 12 years in financial roles of increasing responsibility across different businesses, including roles at the Headquarters in Germany, as well as in Indonesia, China and the USA. He has proven experience in executive management roles and as a principal financial advisor to Boards of Directors. Before joining Lundbeck in August 2022, Joerg was with AC Immune SA as Executive Vice President and Chief Financial Officer since 2017, where he oversaw Finance and various corporate functions. Prior to AC Immune, he served as Senior Vice President and Head of Group Controlling for Unternehmensgruppe Theo Mueller.

Joerg is a German national. He holds a Bachelor of Business Administration from Baylor University – Hankamer School of Business, Texas, US and an MBA with Distinction from London Business School, UK.

Keld Flintholm Jørgensen began his career at Arthur Andersen Corporate Assurance Services in Copenhagen. In 2000, he moved to F. Hoffmann La Roche’s headquarter in Basel, Switzerland, where he held different roles within Group risk management and Strategic Planning for the Pharma Division. In 2005, he relocated to the Baltics and became part of the leadership team responsible for established the first Roche sales affiliates in the region. Subsequently, he returned to Switzerland as Head of Finance and Business Partnering for the Swiss sales affiliate. From 2011, he moved to Roche Pharma Partnering as Director Strategic Partnering and successfully executed multiple strategic projects, partnering agreements and M&A deals across different therapy areas, including neuroscience. In 2017, he was promoted to Global Head Strategic Partnering at Roche and a member of the Late Stage Portfolio Committee. In April 2019, he joined Lundbeck as Executive Vice President and Chief Business Officer.

Keld holds a BSc in Economics & Business Administration and a MSc in Business Economics & Auditing from Copenhagen Business School. 

Keld is a Member of the Board of Directors of Scandion Oncology.

In 1991, Johan Luthman began his career in the pharmaceutical industry in Astra, later AstraZeneca. In 2005, Johan joined Serono as Head of Neuroscience & Immunology Research, and subsequently, in MerckSerono, as Therapy Area Head, Neurology & Immunology. In 2009, he became CEO of biotech start-up GeNeuro. In late 2009, Johan joined Merck as VP & Franchise Integrator for Neuroscience and Ophthalmology. In 2014, he came to Eisai where he was Senior Vice President and Head of Clinical Development. Johan joined Lundbeck as Executive Vice President, R&D in March 2019.

Johan is a Swedish national and is trained as a Doctor of Dental Sciences from the Karolinska Institute, Sweden. He also holds a PhD in Neurobiology and Histology as well as an Associate Professor title from the Karolinska Institute, Sweden.

Johan is a Member of the Board of Directors of Brain+.

Jacob Tolstrup began his career with Abbott Laboratories in 1997. In 1999, he joined Lundbeck and has since been working in several positions including Finance, Investor Relations and Corporate Communication and has worked in Lundbeck’s affiliate in the US for approximately four years. Before taking on the role as Executive Vice President, Commercial Operations, Jacob was head of Corporate Functions which comprised of Corporate Business Development, Corporate Human Resources, Investor Relations and Corporate Communication & Public Affairs.

Jacob holds a Master of Science in Business Administration & Commercial Law from Aalborg University, Denmark and an MBA from European Business College, Munich, Germany.

Jacob is Chairman of the Board of Directors of Pharmacosmos A/S.